Literature DB >> 3262645

Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line.

A Gougos1, M Letarte.   

Abstract

The 44G4 antigen is expressed in high amounts on human endothelial cells and at low levels on leukemic cells of pre-B and myelomonocytic origin. Its level of expression on the pre-B leukemic HOON cell line used for derivation of the corresponding mAb is intermediate but sufficient to permit the purification of the Ag. The molecule isolated by immunoaffinity from HOON is a glycoprotein since it bound to Ricinus communis agglutinin, wheat germ agglutinin, and peanut agglutinin lectins. The Ag was purified 2400-fold from a soluble taurocholate extract of HOON cells by affinity to wheat germ agglutinin-agarose and 44G4-IgG-Sepharose. The purified glycoprotein is likely a homodimer as it migrated on SDS-PAGE with an apparent m.w. of 170,000, nonreduced, and 95,000, reduced. Removal of N-linked oligosaccharides by endoglycosidase F led to a decrease in m.w. of 25,000; if neuraminidase and O-glycanase were also present, the total decrease in m.w. was 33,000 suggesting a polypeptide chain of 62,000 and 8,000 in O-linked substitutions. The glycoprotein digested with N-glycanase, neuraminidase, or O-glycanase could still be immunoprecipitated with the 44G4 mAb indicating that the antigenic epitope resides in the polypeptide. By Western blot analysis, the dissociated but nonreduced protein was reactive with 44G4, whereas the reduced and alkylated protein was not. Therefore, the epitope is dependent on the presence of intact disulfide bond(s). Sequential immunoprecipitation with OKT9 and 44G4 antibodies indicated that these epitopes are present on two distinct molecules and that 44G4 is distinct from the transferrin receptor despite a similar subunit structure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262645

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Lectin affinity chromatography.

Authors:  I West; O Goldring
Journal:  Mol Biotechnol       Date:  1994-10       Impact factor: 2.695

Review 2.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

3.  Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.

Authors:  N Pece; S Vera; U Cymerman; R I White; J L Wrana; M Letarte
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

4.  Insulin resistance in obese Zucker rat (fa/fa) skeletal muscle is associated with a failure of glucose transporter translocation.

Authors:  P A King; E D Horton; M F Hirshman; E S Horton
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Endoglin: a 180-kD endothelial cell and macrophage restricted differentiation molecule.

Authors:  P J O'Connell; A McKenzie; N Fisicaro; S P Rockman; M J Pearse; A J d'Apice
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

Review 6.  Novel biochemical pathways of endoglin in vascular cell physiology.

Authors:  Carmelo Bernabeu; Barbara A Conley; Calvin P H Vary
Journal:  J Cell Biochem       Date:  2007-12-15       Impact factor: 4.429

7.  ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration.

Authors:  Bridgette N Ray; Nam Y Lee; Tam How; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-30       Impact factor: 4.944

8.  Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients.

Authors:  Ana M Blázquez-Medela; Luis García-Ortiz; Manuel A Gómez-Marcos; José I Recio-Rodríguez; Angel Sánchez-Rodríguez; José M López-Novoa; Carlos Martínez-Salgado
Journal:  BMC Med       Date:  2010-12-20       Impact factor: 8.775

9.  Expression and structural features of endoglin (CD105), a transforming growth factor beta1 and beta3 binding protein, in human melanoma.

Authors:  M Altomonte; R Montagner; E Fonsatti; F Colizzi; I Cattarossi; L I Brasoveanu; M R Nicotra; A Cattelan; P G Natali; M Maio
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

10.  Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1.

Authors:  Takako Saito; Marcel Bokhove; Romina Croci; Sara Zamora-Caballero; Ling Han; Michelle Letarte; Daniele de Sanctis; Luca Jovine
Journal:  Cell Rep       Date:  2017-05-30       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.